SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes
- PMID: 34856174
- DOI: 10.1016/S2213-8587(21)00310-7
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes
Conflict of interest statement
AYYC reports honoraria from Abbott, Astra Zeneca, Boehringer Ingelheim, Bayer, Bausch, Eli Lilly, Dexcom, Janssen, Insulet, HLS Therapeutics, Medtronic, Merck, Novo Nordisk, Sanofi, and Takeda.
Comment in
-
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34. doi: 10.1016/S2213-8587(21)00295-3. Epub 2021 Nov 29. Lancet Diabetes Endocrinol. 2022. PMID: 34856173
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
